Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: Void who wrote (594)	7/14/1998 11:11:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 1906

The table that ligand uses in its annual report: home.att.net indicates that a preclinical molecule has been SELECTED. I'm not sure that the drawing board is as far back as you seem to think it is.

To: Void who wrote (594)	7/15/1998 5:35:00 PM
From: Henry Niman	Respond to of 1906

Void, I have now had a chance to read the entire article and the quote that you posted is really the only info on species specificity. I have re-read the paragraph and Rosen does seem to be just talking about SB247464, when he discusses the mouse specificity. When he talks about the "several drawing boards", he does not indicate that they have not found a human-active compound when these other avenues were explored. The article does address your question about SB247464 moving into the clinic, and LGND indicates that the molecule will be used to explore its mechanism of action (in mice) and its structure will provide a prototype to find related molecules that are human-active). As I said in February, I think that LGND does have a human-active compound(s) and it is in pre-clinical testing (which seems to be borne out by the pipeline table at home.att.net which indicates that a compound has been identified and SELECTED. Robinson's comments on SBH "gobbling up" LGND's targets also supports the conclusion that the programs offer considerable promise and they are move forward and expanding at a rapid rate.

To: Void who wrote (594)	7/16/1998 12:22:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 1906

I think that there is a bit on confusion with regard to the pipeline as well as what exactly a "human-active" G-CSF mimic is. The table that I put up at home.att.net is not a table that is predicting anything. It comes from LGND's 1997 annual report and it merely represents progress to date (i.e. the progress has already happened). The above table is a more graphical version of the table at home.att.net which is actually taken from LGND's SEC filing: edgar-online.com The molecule defined in the Science paper was deemed to be mouse-specific because it mimicked G-CSF in mouse cell lines and animals, but did not work in human cell lines. It was not placed into patients but the molecule that does enter the clinic will be tested on human cell lines in pre-clinical tests. I think that LGND does indeed have a molecule that is human-active which was based on human cell lines. Obviously there have been no human trials yet. The human-reactive molecule has not been announced and an IND has not been filed.